GLP-1 Telehealth Providers in New York

Yes. New York fully permits telehealth prescribing of GLP-1 medications and has some of the broadest provider availability.

Coverage varies by plan. New York has enacted legislation expanding access to obesity treatments, but specific coverage depends on your insurer.

Yes. New York has the widest provider availability alongside California, with virtually all major platforms operating in the state.

New York Medicaid covers some GLP-1 medications for weight management, but coverage depends on your managed care plan, your BMI, and documented comorbidities. Prior authorization is required. Coverage has expanded in recent years but remains inconsistent across plans. Contact your specific Medicaid managed care organization to confirm whether your medication and indication are covered.

After FDA removed semaglutide from the drug shortage list in early 2025, 503B outsourcing compounding ended. New York-licensed 503A pharmacies may still compound for individual prescriptions in specific circumstances. This pathway is narrower than it was in 2024. Ask your telehealth provider whether they work with a licensed 503A compounding pharmacy that can still fulfill these prescriptions.

No referral is required for a telehealth GLP-1 evaluation in New York. Insurance, including certain Medicaid plans, typically requires prior authorization before filling brand-name GLP-1 medications. Cash-pay telehealth programs operate without this requirement. Most complete intake and issue a prescription decision within 24–72 hours.

New York residents can access async telehealth GLP-1 programs with prescription decisions in 24–48 hours for straightforward cases. Synchronous video visits are typically schedulable within 2–5 days. Once prescribed, medication ships to your New York address — expect 3–7 days for delivery. Some pharmacies offer expedited shipping.